Differences in the Inflammatory Response and Corticoid Responsiveness of Human Lung Macrophages and Parenchymal Explants Exposed to Cigarette Smoke Extracts
- PMID: 40344364
- PMCID: PMC12061798
- DOI: 10.1111/bcpt.70046
Differences in the Inflammatory Response and Corticoid Responsiveness of Human Lung Macrophages and Parenchymal Explants Exposed to Cigarette Smoke Extracts
Abstract
Smoking is the main cause of chronic obstructive pulmonary disease (COPD) and is associated with corticosteroid resistance. Given the paucity of data on human lung preparations, macrophages (LMs), and parenchymal explants (LPEs) were exposed to cigarette smoke extracts (CSE) in the presence or absence of lipopolysaccharide (LPS). Moreover, LMs and LPEs were treated with budesonide prior exposure to CSE or LPS. The levels of cytokines (TNF-α, IL-6) and chemokines (CCL2, CCL4, CXCL1, CXCL5, and CXCL8) in the supernatants were measured using ELISAs. In LMs, exposure to CSE was not associated with significant difference in the production of cytokines and chemokines, with the notable exception of greater CXCL8 production. The results were generally the same for LPEs. CSE exposure did not potentiate the LPS-induced production of the cytokines and chemokines and even tended to reduce this production in LMs and LPEs. Lastly, CSE exposure inhibited budesonide's anti-inflammatory activity in LMs but not in LPEs. This study extends the data on the CSE inflammatory effects and its inhibition of corticosteroid efficacy in human lung preparations. Our findings question the relevance of these preparations with regard to the long-term toxicity of smoking and the corticosteroid resistance observed in smokers and in patients with COPD.
Keywords: chronic obstructive pulmonary disease; cigarette smoke extract; corticosteroid resistance; cytokine; glucocorticoid; lung explant; lung macrophage.
© 2025 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Conflict of interest statement
Nicolas Roche has given paid lectures and/or done consulting for Boehringer Ingelheim, GlaxoSmithKline, Astra Zeneca, Sanofi, Chiesi, Pfizer, Novartis, Austral, Biosency, Zambon, MSD, and Menarini all unrelated to the present work; Nicolas Roche reports participation in research projects funded by Boehringer‐Ingelheim, Pfizer, and GlaxoSmihLine, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. Nicolas Roche is European Respiratory Society Science Council Chair. Martin Dres reports participation in research projects funded by GlaxoSmihKLine and Fisher & Paykel all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. Philippe Devillier has given paid lectures and/or done consulting for Boehringer Ingelheim, GlaxoSmithKline, Astra Zeneca, Chiesi, and Menarini all unrelated to the present work. The remaining authors report no potential conflicts of interest.
Figures
References
-
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2025 Report). GOLD‐2025‐Report‐v1.0‐15Nov2024_WMV.pdf. https://goldcopd.org/2025‐gold‐report/.
-
- Thomson N. C., Polosa R., and Sin D. D., “Cigarette Smoking and Asthma,” Journal of Allergy and Clinical Immunology. In Practice 10, no. 11 (2022): 2783–2797. - PubMed
-
- Global Strategy for Asthma Management and Prevention (2024 update). GINA‐2024‐Strategy‐Report‐24_05_22_WMS.pdf. https://ginasthma.org/2024‐report/.
-
- Facchinetti F., Amadei F., Geppetti P., et al., “Alpha, Beta‐Unsaturated Aldehydes in Cigarette Smoke Release Inflammatory Mediators From Human Macrophages,” American Journal of Respiratory Cell and Molecular Biology 37, no. 5 (2007): 617–623. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
